Early and rapid detection of neuron-specific enolase
(NSE) is highly
significant, as it is putative biomarker for small-cell lung cancer
as well as COVID-19. Electrochemical techniques have attracted substantial
attention for the early detection of cancer biomarkers due to the
important properties of simplicity, high sensitivity, specificity,
low cost, and point-of-care detection. This work reviews the clinically
relevant labeled and label-free electrochemical immunosensors developed
so far for the analysis of NSE. The prevailing role of nanostructured
materials as electrode matrices is thoroughly discussed. Subsequently,
the key performances of various immunoassays are critically evaluated
in terms of limit of detection, linear ranges, and incubation time
for clinical translation. Electrochemical techniques coupled with
screen-printed electrodes developing market level commercialization
of NSE sensors is also discussed. Finally, the review concludes with
the current challenges associated with available methods and provides
a future outlook toward commercialization opportunities for easy detection
of NSE.